These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2139337)

  • 21. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol.
    Baez MA; Garg DC; Jallad NS; Weidler DJ
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):63S-67S. PubMed ID: 2939869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension.
    Shionoiri H; Yasuda G; Yoshimura H; Umemura S; Miyajima E; Miyakawa T; Takagi N; Kaneko Y
    J Cardiovasc Pharmacol; 1987 Jul; 10(1):90-5. PubMed ID: 2441160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency.
    Anderton JL; Notghi A
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():52-7. PubMed ID: 2148196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure.
    Carlson RV; Bailey RR; Begg EJ; Cowlishaw MG; Sharman JR
    Clin Pharmacol Ther; 1986 Nov; 40(5):561-6. PubMed ID: 2945688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment.
    Faulkner JK; Himanen P; Karjalainen U; Saraste M
    Eur J Clin Pharmacol; 1987; 31(6):685-93. PubMed ID: 2951261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure.
    Mori Y; Matsubara H; Nose A; Shibasaki Y; Masaki H; Kosaki A; Okigaki M; Fujiyama S; Tanaka-Uchiyama Y; Hasegawa T; Iba O; Tateishi E; Amano K; Iwasaka T
    Hypertens Res; 2001 Jul; 24(4):359-63. PubMed ID: 11510747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison.
    Lijnen P; Fagard R; Staessen J; Amery A
    Methods Find Exp Clin Pharmacol; 1990 Oct; 12(8):563-73. PubMed ID: 2151197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function.
    Larsson R; Karlberg BE; Gelin A; Aberg J; Regårdh CG
    J Clin Pharmacol; 1990 Nov; 30(11):1020-30. PubMed ID: 2243149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.
    Lindner UK; von Manteuffel GE; Stafunsky M
    Am Heart J; 1988 Dec; 116(6 Pt 2):1814-20. PubMed ID: 2904756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 24-hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo.
    Smyth P; Pringle S; Jackson G; Lorimer AR
    Eur J Clin Pharmacol; 1988; 34(6):613-8. PubMed ID: 2971549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter trial of doxazosin in West Germany.
    Rosenthal J
    Am J Cardiol; 1987 May; 59(14):40G-45G. PubMed ID: 2884852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein.
    Oliveros-Palacios MC; Godoy-Godoy N; Colina-Chourio JA
    Am J Cardiol; 1991 Jan; 67(2):157-61. PubMed ID: 1824806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of alpha 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension.
    Wilner KD; Ziegler MG
    Am J Cardiol; 1987 May; 59(14):82G-86G. PubMed ID: 2884858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of doxazosin in hypertension therapy.
    Hayduk K
    Am J Cardiol; 1987 May; 59(14):35G-39G. PubMed ID: 2884851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter study of doxazosin in the treatment of patients with mild or moderate essential hypertension and concomitant intermittent claudication.
    Catalano M; Libretti A
    Am Heart J; 1991 Jan; 121(1 Pt 2):367-71. PubMed ID: 1824663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study.
    Corral JL; López NC; Pecorelli A; Rincón LA; Terán VD
    Am Heart J; 1991 Jan; 121(1 Pt 2):352-6. PubMed ID: 1824660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-response clarification in early drug development.
    Meredith PA; Elliott HL; Donnelly R; Reid JL
    J Hypertens Suppl; 1991 Dec; 9(6):S356-7. PubMed ID: 1840197
    [No Abstract]   [Full Text] [Related]  

  • 38. A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.
    Elliott HL; Meredith PA; Sumner DJ; McLean K; Reid JL
    Br J Clin Pharmacol; 1982 May; 13(5):699-703. PubMed ID: 6123342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension.
    Fukiyama K; Omae T; Iimura O; Yoshinaga K; Yagi S; Inagaki Y; Ishii M; Kaneko Y; Yamada K; Ijichi H
    Am Heart J; 1991 Jan; 121(1 Pt 2):317-22. PubMed ID: 1824654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
    Taylor SH
    Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.